Last reviewed · How we verify
PIPECURONIUM
Pipecuronium is a small molecule drug in the pipecuronium class that targets the acetylcholine receptor. It was originally developed and is currently owned by a pharmaceutical company. Pipecuronium is FDA-approved for muscle relaxation and function, with a half-life of 1.9 hours. It is off-patent and has no generic manufacturers. As a muscle relaxant, pipecuronium is used to facilitate surgical procedures.
At a glance
| Generic name | PIPECURONIUM |
|---|---|
| Drug class | pipecuronium |
| Target | Acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1990 |
Approved indications
- Muscle relaxation, function
Common side effects
Drug interactions
- streptomycin
- tobramycin
Key clinical trials
- Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Propofol Anesthesia (PHASE4)
- Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia (PHASE4)
- Effects of Low-pressure Pneumoperitoneum Associated With Deep Pipecuronium-induced Neuromuscular Blockade on Hemodynamic Parameters for High Cardiovascular Risk Patient Undergoing General Anesthesia
- Anesthesia Standard Operating Procedure During On-pump Coronary Artery Bypass Grafting (NA)
- Sugammadex Efficacy and Safety for Reversal of Pipecuronium-induced Neuromuscular Blockade (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |